Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elevai Labs, Inc. - Common Stock (NQ: ELAB )

0.5251 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 720
Open 0.5251
Bid (Size) 0.5300 (18)
Ask (Size) 0.5688 (2)
Prev. Close 0.5251
Today's Range 0.5251 - 0.5251
52wk Range 0.5225 - 4.244
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
From Elevai Labs Inc.
Via GlobeNewswire

Performance

YTD
-72.22%
-72.22%
1 Month
-15.43%
-15.43%
3 Month
-17.97%
-17.97%
6 Month
-70.50%
-70.50%
1 Year
-84.56%
-84.56%

More News

Read More
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
From Elevai Labs Inc.
Via GlobeNewswire
ELAB Stock Earnings: Elevai Labs Reported Results for Q1 2024
Via InvestorPlace
ELAB Stock Earnings: Elevai Labs Reported Results for Q4 2023
Via InvestorPlace
Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Via News Direct
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
From Elevai Labs Inc.
Via GlobeNewswire
12 Consumer Staples Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
From Elevai Labs Inc.
Via GlobeNewswire
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
From Elevai Labs Inc.
Via GlobeNewswire
12 Consumer Staples Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
From Elevai Labs Inc.
Via GlobeNewswire
Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Is Revelation Biosciences (REVB) Stock Down 62% Today?
Via InvestorPlace
Why Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today?
Via InvestorPlace
Why Is Elevai Labs (ELAB) Stock Up 57% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.